S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
3rd Massive Dollar Upheaval Has Started (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Here's Bill Bonner's "4th and Final Prediction" (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
3rd Massive Dollar Upheaval Has Started (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Here's Bill Bonner's "4th and Final Prediction" (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
3rd Massive Dollar Upheaval Has Started (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Here's Bill Bonner's "4th and Final Prediction" (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
3rd Massive Dollar Upheaval Has Started (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Here's Bill Bonner's "4th and Final Prediction" (Ad)
NASDAQ:PLSE

Pulse Biosciences - PLSE Stock Forecast, Price & News

$1.60
-0.20 (-11.11%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.60
$1.78
50-Day Range
$1.52
$2.58
52-Week Range
$1.41
$29.16
Volume
51,973 shs
Average Volume
190,929 shs
Market Capitalization
$59.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.17

Pulse Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
597.9% Upside
$11.17 Price Target
Short Interest
Bearish
11.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.66) to ($1.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

859th out of 1,122 stocks

Surgical & Medical Instruments Industry

81st out of 112 stocks

PLSE stock logo

About Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PLSE. HC Wainwright cut Pulse Biosciences from a "buy" rating to a "neutral" rating in a report on Friday, May 13th. StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research note on Thursday, August 4th. Finally, Stephens cut Pulse Biosciences from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 12th.

Pulse Biosciences Price Performance

Shares of Pulse Biosciences stock traded down $0.09 during trading on Wednesday, reaching $1.71. 100 shares of the company's stock were exchanged, compared to its average volume of 78,094. Pulse Biosciences has a 1-year low of $1.41 and a 1-year high of $29.16. The firm's 50-day moving average price is $1.82 and its 200 day moving average price is $3.49.

Pulse Biosciences (NASDAQ:PLSE - Get Rating) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Pulse Biosciences had a negative net margin of 2,866.34% and a negative return on equity of 186.19%. During the same period in the prior year, the business posted ($0.57) earnings per share. On average, sell-side analysts expect that Pulse Biosciences will post -1.66 earnings per share for the current fiscal year.

Receive PLSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter.

PLSE Stock News Headlines

Recap: Pulse Biosciences Q2 Earnings
A Preview Of Pulse Biosciences Earnings
Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com
Pulse Biosciences, Inc. Misses Q1 EPS by 6c
Pulse Biosciences, Inc. Announces Rights Offering
Pulse Biosciences, Inc. Misses Q4 EPS by 1c
See More Headlines
Receive PLSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter.

PLSE Company Calendar

Last Earnings
8/10/2022
Today
8/17/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLSE
Fax
N/A
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.17
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$8.50
Forecasted Upside/Downside
+597.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-63,660,000.00
Net Margins
-2,866.34%
Pretax Margin
-2,866.34%

Debt

Sales & Book Value

Annual Sales
$1.42 million
Book Value
$0.63 per share

Miscellaneous

Free Float
16,707,000
Market Cap
$59.40 million
Optionable
Optionable
Beta
1.94

Key Executives

  • Mr. Darrin R. Uecker (Age 56)
    Pres, CEO & Director
    Comp: $511.42k
  • Ms. Sandra A. Gardiner (Age 56)
    Exec. VP of Fin. & Admin., CFO and Treasurer
    Comp: $417.92k
  • Mr. Mitchell E. Levinson (Age 62)
    Chief Strategy Officer & Director
    Comp: $449.02k
  • Dr. Richard Nuccitelli Ph.D.
    Chief Science Officer
  • Mr. Kenneth B. Stratton Esq. (Age 53)
    J.D., Gen. Counsel & Corp. Sec.
  • Dr. Holly Hartman J.D.
    Ph.D., VP of Bus. Devel. & Corp. Strategy
  • Ms. Patty Perla
    VP of HR
  • Mr. David Danitz
    Sr. VP of Engineering
  • Mr. Kevin Danahy (Age 51)
    Chief Commercial Officer













PLSE Stock - Frequently Asked Questions

Should I buy or sell Pulse Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PLSE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLSE, but not buy additional shares or sell existing shares.
View PLSE analyst ratings
or view top-rated stocks.

What is Pulse Biosciences' stock price forecast for 2022?

3 brokers have issued 1-year target prices for Pulse Biosciences' shares. Their PLSE share price forecasts range from $8.50 to $13.00. On average, they anticipate the company's share price to reach $11.17 in the next twelve months. This suggests a possible upside of 597.9% from the stock's current price.
View analysts price targets for PLSE
or view top-rated stocks among Wall Street analysts.

How have PLSE shares performed in 2022?

Pulse Biosciences' stock was trading at $14.81 at the start of the year. Since then, PLSE stock has decreased by 89.2% and is now trading at $1.60.
View the best growth stocks for 2022 here
.

When is Pulse Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our PLSE earnings forecast
.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc. (NASDAQ:PLSE) issued its quarterly earnings data on Wednesday, August, 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.07. Pulse Biosciences had a negative net margin of 2,866.34% and a negative trailing twelve-month return on equity of 186.19%. During the same quarter last year, the business posted ($0.57) earnings per share.

What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?

2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX).

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.

What is Pulse Biosciences' stock symbol?

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Westside Investment Management Inc. (0.60%), Millennium Management LLC (0.40%), Northern Trust Corp (0.24%), Griffin Asset Management Inc. (0.23%), Occudo Quantitative Strategies LP (0.20%) and State Street Corp (0.17%).
View institutional ownership trends
.

How do I buy shares of Pulse Biosciences?

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulse Biosciences' stock price today?

One share of PLSE stock can currently be purchased for approximately $1.60.

How much money does Pulse Biosciences make?

Pulse Biosciences (NASDAQ:PLSE) has a market capitalization of $59.40 million and generates $1.42 million in revenue each year. The company earns $-63,660,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis.

How many employees does Pulse Biosciences have?

The company employs 142 workers across the globe.

How can I contact Pulse Biosciences?

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The official website for the company is www.pulsebiosciences.com. The company can be reached via phone at (510) 906-4600 or via email at ir@pulsebiosciences.com.

This page (NASDAQ:PLSE) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.